...
首页> 外文期刊>International Journal of Nanomedicine >SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
【24h】

SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study

机译:负载SN38的<100 nm靶向脂质体可改善不良的溶解性并最大程度地减少突发释放和毒性:体外和体内研究

获取原文
           

摘要

Background: SN38 (7-ethyl-10-hydroxycamptothecin) is a camptothecin derivative acts against various tumors. However, SN38 is hydrolyzed in the physiological environment (pH 7.4), and this instability interferes with its potential therapeutic effect. Our objective was to investigate SN38-loaded liposomes to overcome the poor solubility of SN38 and its biodistribution, which further diminish its toxicity. Materials and methods: The sub-100 nm targeted liposomes was employed to deliver SN-38 and evaluate the characterization, release behaviors, cytotoxicity, in vivo pharmacokinetics and biochemical assay. Results: The SN38-loaded targeted liposomes consisted of small (100.49 nm) spherical nanoparticles with negative charge (-37.93 mV) and high entrapment efficiency (92.47%). The release behavior of the SN38-loaded targeted liposomes was fitted with Higuchi kinetics ( R 2=0.9860). Free SN38 presented initial burst release. The IC50 for the SN38-loaded targeted liposomes (0.11 μM) was significantly lower than for the SN38 solution (0.37 μM) in the MCF7 cell line ( P <0.01). Confocal laser scanning microscopy also confirmed highly efficient accumulation in the MCF7 cells. Pharmacokinetics demonstrated that the SN38-loaded targeted liposomes had a slightly increased half-life and mean residence time and decreased area under the concentration–time curve and maximum concentration. The results suggested that retention was achieved while the exposure of SN38 was significantly decreased. A noninvasive in vivo imaging system also showed that the targeted liposomes selectively targeted MCF7 tumors. In vivo toxicity data demonstrated that the decrease in platelets was significantly improved by SN38-loaded targeted liposomes, and diarrhea was not observed in BALB/c mice. Conclusion: In summary, SN38-loaded targeted liposomes could be a good candidate for application in human breast cancer.
机译:背景:SN38(7-乙基-10-羟基喜树碱)是一种喜树碱衍生物,可对抗多种肿瘤。但是,SN38在生理环境(pH 7.4)中会水解,这种不稳定性会干扰其潜在的治疗效果。我们的目的是研究负载SN38的脂质体,以克服SN38的不良溶解性及其生物分布,从而进一步降低其毒性。材料和方法:使用100 nm以下的靶向脂质体递送SN-38,并评估其表征,释放行为,细胞毒性,体内药代动力学和生化测定。结果:负载SN38的靶向脂质体由小的(100.49 nm)球形纳米颗粒组成,带有负电荷(-37.93 mV)和高包封率(92.47%)。负载SN38的靶向脂质体的释放行为符合Higuchi动力学(R 2 = 0.9860)。免费SN38提供了初始突发版本。 SN38靶向脂质体的IC 50 (0.11μM)显着低于MCF7细胞系中SN38溶液(0.37μM)(P <0.01)。共聚焦激光扫描显微镜也证实了MCF7细胞中的高效积累。药代动力学证明,在浓度-时间曲线和最大浓度下,负载SN38的靶向脂质体的半衰期和平均停留时间略有增加,并且面积减小。结果表明,在保留的同时,SN38的暴露显着降低。无创体内成像系统还显示,靶向脂质体选择性靶向MCF7肿瘤。体内毒性数据表明,加载SN38的靶向脂质体可显着改善血小板的减少,而在BALB / c小鼠中未观察到腹泻。结论:总而言之,载有SN38的靶向脂质体可能是在人乳腺癌中应用的良好候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号